Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrahydrofuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL3626048 | 1.00 | — | — | |
| Tetrahydrofuran SCHEMBL21496006 | 0.95 | — | — | |
| Tetrahydrofuran SCHEMBL27262153 | 0.95 | — | — | |
| Tetrahydrofuran SCHEMBL25278588 | 0.91 | — | — | |
| Tetrahydrofuran SCHEMBL11793203 | 0.91 | — | — | |
| Tetrahydrofuran SCHEMBL27261909 | 0.91 | — | — | |
| Tetrahydrofuran SCHEMBL2219545 | 0.86 | — | — | |
| Tetrahydrofuran SCHEMBL1278401 | 0.86 | — | — | |
| Tetrahydrofuran SCHEMBL15821488 | 0.86 | — | — | |
| Tetrahydrofuran SCHEMBL2177525 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3385253-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Lantheus Medical Imaging, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-1713512-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9718786-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| EP-1051461-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR, William C. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999066009-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR WILLIAM C (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0954558-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR, William C. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1999054290-A1 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998026028-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0589867-B1 | SENSING SURFACES CAPABLE OF SELECTIVE BIOMOLECULAR INTERACTIONS, TO BE USED IN BIOSENSOR SYSTEMS | PHARMACIA BIOSENSOR AB (SE) | 1996-04-10 | — | — | EP | disclosed |
| US-5436161-A | Matrix coating for sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systems | PHARMACIA BIOSENSOR AB (SE) | 1995-07-25 | — | — | US | disclosed |
| EP-0589867-A1 | SENSING SURFACES CAPABLE OF SELECTIVE BIOMOLECULAR INTERACTIONS, TO BE USED IN BIOSENSOR SYSTEMS. | PHARMACIA BIOSENSOR AB (SE) | 1994-04-06 | — | — | EP | disclosed |
| US-5242828-A | SENSING SURFACES CAPABLE OF SELECTIVE BIOMOLECULAR INTERACTIONS, TO BE USED IN BIOSENSOR SYSTEMS | PHARMACIA BIOSENSOR AB (SE) | 1993-09-07 | — | — | US | disclosed |
| WO-1990005303-A1 | SENSING SURFACES CAPABLE OF SELECTIVE BIOMOLECULAR INTERACTIONS, TO BE USED IN BIOSENSOR SYSTEMS | PHARMACIA AB (SE) | 1990-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009763-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | ALDH1A1 2228/4885TTR 283/4885TSHR 2215/4885 |
| US-20190127333-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | ALDH1A1 2228/4885TTR 283/4885TSHR 2215/4885 |
| US-20160130235-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | ALDH1A1 2228/4885TTR 283/4885TSHR 2215/4885 |
| US-10125106-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | ALDH1A1 2228/4885TTR 283/4885TSHR 2215/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | ALDH1A1 2228/4885TTR 283/4885TSHR 2215/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | ALDH1A1 2228/4885TTR 283/4885TSHR 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.